FORIMTAMIG
UNII 1GK8Z1OT1R

Substance Identification & Data

This profile provides standardized clinical and technical data for Forimtamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 1GK8Z1OT1R.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2649379-96-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

1GK8Z1OT1R

CAS Registry Number

2649379-96-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

FORIMTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C189961

National Cancer Institute reference terminology for clinical and research data.

INN ID

12346

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-143

Identifier assigned by the United States Adopted Names Council.

Substance Type

Forimtamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Forimtamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Forimtamig

Common Names & Synonyms

FORIMTAMIG [USAN]

Forimtamig [WHO-DD]

Immunoglobulin G1 [459-alanine,460-alanine,579-cysteine,554-glycine,591-tryptophan], anti-(human G protein-coupled receptor GPRC5D) (human-Rattus norvegicus γ1-chain N-terminal fragment) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin G1 anti-(human CD3 antigen ε-chain) (human λ-chain V-J region) fusion protein with peptide linker (SS) fusion protein with immunoglobulin G1 (human γ1-chain C-terminal fragment), (445→232′′)-disulfide with immunoglobulin G1 anti-(human CD3 antigen ε-chain) (human γ1-chain V-D-J region) fusion protein with immunoglobulin G1 [1-alanine,2-serine] (human κ-chain C region), (451→226′),(454→229′),(579→349′)-tris(disulfide) with immunoglobulin G1 [147-glutamic acid,213-glutamic acid,234-alanine,235-alanine,329-glycine,349-cysteine,366-serine,368-alanine,407-valine] anti-(human G protein-coupled receptor GPRC5D) (human-Rattus norvegicus γ1-chain), disulfide with [127-arginine,128-lysine] immunoglobulin G1 anti-(human G protein-coupled receptor GPRC5D) (human κ-chain)

Immunoglobulin G1-lambda/kappa with crossed domains, anti-[Homo sapiens GPRC5D (G proteincoupled receptor class C group 5 member D)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, bispecific, trivalent; gamma-lambda heavy chain bispecific, anti-GPRC5D and anti-CD3E (VH-CH1-V-lambda-CH1-CH2-CH3) (1- 672) [humanized VH anti-GPRC5D (Homo sapiens IGHV3-23*03 (91.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117) - Homo sapiens IGHG1*01, G1m17 (CH1 K26>E (147), K119>E (213), K120 (214) (118-215), hinge 1-6 (216-221)) (118-221) - 10-mer bis(tetraglycyl-seryl) linker (222-231) -Musmus/Homsap VLAMDDA anti-CD3E (Mus musculus IGLV1*01 (81.2%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (80.0%) -IGLJ3*02 (100%), CDRIMGT [9.3.9] (257-265.283-285.322-330))(232-340) -2-mer biseryl linker (341-342) -Homo sapiens IGHG1*01, G1m17,1, G1v14-49 CH2 A1.3, A1.2, G114,G1v32 CH3 W22 (knob) (CH1 K120 (439) (343-440), hinge 1-15 (441-455), CH2 L1.3>A (459), L1.2>A (460), P114>G (554) (456- 565), CH3 S10>C (579), D12 (581), L14 (583), T22>W (591) (566-670), CHS (671- 672)) (343-672)], (220-218')-disulfide with kappa light chain anti-GPRC5D (1'-218') [humanized V-KAPPA (Homo sapiens IGKV3- 20*01 (83.8%) -IGKJ5*01 (91.7%), CDR-IMGT [10.3.9] (27-36.54-56.93- 101)) (1'-111') -Homo sapiens IGKC*01 (98.1%), E12>R (127), Q13>K (128), Km3 A45.1 (157), V101 (195) (112'-218')], (445-232''')-disulfide with light chain with crossed VH anti-CD3E (1'''-232''') [humanized VH (Homo sapiens IGHV3-23*03 (87.0%) -IGHJ4*01 (86.7%), CDR-IMGT [8.10.16] (26-33.51-60.99-114)) (1'''-125''') -Homo sapiens IGKC*01 (99.1%), R1.4>A (126), T1.3>S (127), Km3 A45.1 (171), V101 (209) (126'''-232''')]; gamma1 heavy chain anti-GPRC5D (1''-447'') [humanized VH (Homo sapiens IGHV3-23*03 (91.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1''-117'') -Homo sapiens IGHG1*01, G1m17,1, G1v14-49 CH2 A1.3, A1.2, G114, G1v33 CH3 S22, A24, V86 (hole) (CH1 K26>E (147), K119>E (213), K120(214) (118''-215''), hinge1-15 (216''-230''), CH2 L1.3>A (234), L1.2>A (235), P114>G (329) (231''- 340''), CH3 Y5>C (349), D12 (356), L14 (358), T22>S (366), L24>A (368), Y86>V (407) (341''-445''), CHS (446''- 447'')) (118''-447'')], (220''-218'''')-disulfide with kappa light chain antiGPRC5D(1''''-218'''') [humanized V-KAPPA (Homo sapiens IGKV3-20*01 (83.8%) -IGKJ5*01 (91.7%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1''''-111'''') -Homo sapiens IGKC*01 (98.1%), E12>R (127), Q13>K (128), Km3 A45.1 (157), V101 (195) (112''''- 218'''')]; dimer (451- 226'':454-229'':579-349'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

forimtamig [INN]